The Phase 2 obesity publication described dose-dependent increases in heart rate that peaked at 24 weeks and declined later. The result is one of several safety observations reported by investigators.
A monitored safety measure
A change in heart rate and a cardiovascular outcome such as a heart attack are different endpoints. A trial designed around weight change may not be sized or followed long enough to measure major cardiovascular outcomes precisely.
How to interpret the evidence
Use the safety table for the observed signal and look for a dedicated outcomes trial when the question involves clinical cardiovascular events.
This research summary focuses on a defined endpoint or safety observation. Its relevance depends on the study’s population and follow-up.